Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1976; 35(03): 748-750DOI: 10.1055/s-0038-1647973 International Committee Communications Schattauer GmbH Report of the Task Force on the Clinical Use of Factor IX Concentrates Doris Ménaché 1 From Service Central d’Immunologie et Hématologie, Hõpital Beaujon, 92-Clichy and CHU Xavier Bichat, Paris (France) › Author Affiliations Recommend Article Abstract Buy Article Full Text References References 1 Cash J. D, Dalton R. G, Mtodleton S, Smith J. K. 1975; Studies on the thrombogenicity of Scottish Factor IX concentrates in dogs. Thrombosis et Diathesis Haemorrhagica 33: 632. 2 Hoofnagle J. H, Aronson D. L, Roberts H. R. 1975; Serological evidence for hepatitis B virus in patients with hemophilia B. A multicenter study. Thrombosis et Diathesis Haemorrhagica 33: 606. 3 Kingdon H. S, Lundblad R. L, Veltkamp J. J, Aronson D. L. 1975; Potentially thrombogenic materials in factor IX concentrates. Thrombosis et Diathesis Haemorrhagica 33: 617. 4 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica 33: 640. 5 Ménaché D. 1975; a Clinical use of factor IX concentrates. Thrombosis et Diathesis Haemorrhagica 33: 597. 6 Ménaché D. 1975; b Factor IX concentrates. Thrombosis et Diathesis Haemorrhagica 33: 600. 7 Ménaché D, Roberts H. R. 1975; Summary report and recommendations of the Task Force members and consultants. Thrombosis et Diathesis Haemorrhagica 33: 645. 8 Roberts H. R, Blatt P. M. 1975; Post transfusion hepatitis following the use of prothrombin complex concentrates. Thrombosis et Diathesis Haemorrhagica 33: 606.
